Juniper Therapeutics Acquires Exclusive Rights for SAR Registration for Anti-Viral COVID-19 Drug from Ping An-Shionogi Hong Kong for Singapore

Posted on by

First drug to show both clinical symptomatic efficacy for five typical Omicron-related symptoms and antiviral efficacy SINGAPORE, Dec. 21, 2023 /PRNewswire/ — Singapore-headquartered Juniper Therapeutix, a science-led healthcare company focused on commercializing novel therapies, today…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.